High-density lipoprotein impedes glycation of low-density lipoprotein

Diabetes and Vascular Disease Research

Volumn 10, Issue 2, 2013, Pages 152-160

  Younis, Nahla N ^a,b   Soran, Handrean ^a   Charlton Menys, Valentine ^a   Sharma, Reena ^a   Hama, Salam ^a   Pemberton, Philip ^c   Elseweidy, Mohamed M ^b   Durrington, Paul N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Zagazig University   (Egypt)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Glycation; high density lipoprotein; lipid peroxidation; low density lipoprotein; paraoxonasel

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITROGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROPHORETIC MOBILITY; FEMALE; GLYCATION; HETEROLOGOUS EXPRESSION; HUMAN; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; PROTEIN ISOLATION;

ADULT; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; FEMALE; GLUCOSE; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED;

EID: 84874075706     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112454309     Document Type: Article

References (61)

1. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009 ; 302: 1993-2000
2. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010 ; 30: 2311-2316
3. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond). 2009 ; 116: 87-98
4. Mackness MI, Abbott C, Arrol S, et al. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993 ; 294: 829-834
5. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001 ; 21: 473-480
6. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995 ; 115: 243-253
7. Negre-Salvayre A, Dousset N, Ferretti G, et al. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med. 2006 ; 41: 1031-1040
8. Klimov AN, Gurevich VS, Nikiforova AA, et al. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis. 1993 ; 100: 13-18
9. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008 ; 299: 1265-1276
10. Younis NN, Soran H, Sharma R, et al. Lipoprotein glycation and atherogenesis. Clin Lipidol. 2009 ; 4: 781-790
11. Tames FJ, Mackness MI, Arrol S, et al. Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis. 1992 ; 93: 237-244
12. Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995 ; 15: 1812-1818
13. Ikeda Y, Suehiro T, Inoue M, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1998 ; 47: 598-602
14. Mackness B, Durrington PN, Abuashia B, et al. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond). 2000 ; 98: 355-363
15. Kempler P, Tesfaye S, Chaturvedi N, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med. 2002 ; 19: 900-909
16. Hofer SE, Bennetts B, Chan AK, et al. Association between PON 1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications. 2006 ; 20: 322-328
17. Gallego PH, Craig ME, Duffin AC, et al. Association between p. Leu54Met polymorphism at the paraoxonase-1 gene and plantar fascia thickness in young subjects with type 1 diabetes. Diabetes Care. 2008 ; 31: 1585-1589
18. Zhou H, Tan KC, Shiu SW, et al. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transplant. 2008 ; 23: 927-933
19. Li C, Gu Q. Protective effect of paraoxonase 1 of high- density lipoprotein in type 2 diabetic patients with nephropathy. Nephrology (Carlton). 2009 ; 14: 514-520
20. Connelly PW, Zinman B, Maguire GF, et al. Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. J Lipid Res. 2009 ; 50: 1216-1222
21. Zoppini G, Negri C, Stoico V, et al. Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. Metabolism. 2012 ; 61: 22-29
22. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications. 2003 ; 17: 16-21
23. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol. 2011 ; 22: 176-185
24. Davidsson P, Hulthe J, Fagerberg B, et al. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol. 2010 ; 30: 156-163
25. Navab M, Reddy ST, Van Lenten BJ, et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011 ; 8: 222-232
26. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003 ; 107: 2775-2779
27. Ikeda Y, Inoue M, Suehiro T, et al. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol. 2009 ; 46: 239-242
28. Soran H, Younis NN, Charlton-Menys V, et al. Variation in paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol. 2009 ; 20: 265-274
29. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 ; 34: 1345-1353
30. Gambino R, Uberti B, Alemanno N, et al. In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control. Atherosclerosis. 2004 ; 173: 103-107
31. El-Saadani M, Esterbauer H, El-Sayed M, et al. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989 ; 30: 627-630
32. Habeeb AF. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem. 1966 ; 14: 328-336
33. Younis N, Charlton-Menys V, Sharma R, et al. Glycation of LDL in non-diabetic people: small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis. 2009 ; 202: 162-168
34. Charlton-Menys V, Liu Y, Durrington PN. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem. 2006 ; 52: 453-457
35. Younis NN, Soran H, Sharma R, et al. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res. 2010 ; 7: 289-295
36. Imanaga Y, Sakata N, Takebayashi S, et al. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis. 2000 ; 150: 343-355
37. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995 ; 96: 2882-2891
38. Rabbani N, Godfrey L, Xue M, et al. Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes. 2011 ; 60: 1973-1980
39. Lindsay RM, Smith W, Lee WK, et al. The effect of delta-gluconolactone, an oxidised analogue of glucose, on the nonenzymatic glycation of human and rat haemoglobin. Clin Chim Acta. 1997 ; 263: 239-247
40. Oda MN, Bielicki JK, Ho TT, et al. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun. 2002 ; 290: 921-927
41. She ZG, Zheng W, Wei YS, et al. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ Res. 2009 ; 104: 1160-1168
42. Mackness B, Durrington PN, Mackness MI. Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Commun. 1998 ; 247: 443-446
43. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998 ; 394: 284-287
44. Birjmohun RS, Vergeer M, Stroes ES, et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. PLoS One. 2009 ; 4: e6809
45. Troughton JA, Woodside JV, Yarnell JW, et al. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis. 2008 ; 197: 556-563
46. Van Himbergen TM, Van Der, Schouw YT, Voorbij HA, et al. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis. 2008 ; 199: 408-414
47. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998 ; 101: 1581-1590
48. Rosenblat M, Vaya J, Shih D, et al. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis. 2005 ; 179: 69-77
49. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011 ; 121: 2693-2708
50. Draganov DI, Teiber JF, Speelman A, et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005 ; 46: 1239-1247
51. Rosenblat M, Gaidukov L, Khersonsky O, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem. 2006 ; 281: 7657-7665
52. Tabet F, Lambert G, Cuesta Torres LF, et al. Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages. Arterioscler Thromb Vasc Biol. 2011 ; 31: 1192-1200
53. Elsøe S, Ahnström J, Christoffersen C, et al. Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis. 2012 ; 221: 91-97
54. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipoprotein function. Diabetologia. 2000 ; 43: 312-320
55. Younis N, Sharma R, Soran H, et al. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol. 2008 ; 19: 378-384
56. Steinbrecher UP, Witztum JL. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes. 1984 ; 33: 130-134
57. Brown BE, Rashid I, Van Reyk DM, et al. Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages. FEBS J. 2007 ; 274: 1530-1541
58. Sobal G, Menzel J, Sinzinger H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. Prostaglandins Leukot Essent Fatty Acids. 2000 ; 63: 177-186
59. Han J, Nicholson AC, Zhou X, et al. Oxidized low density lipoprotein decreases macrophage expression of scavenger receptor B-I. J Biol Chem. 2001 ; 276: 16567-16572
60. Vessby B, Gustafson S, Chapman MJ, et al. Lipoprotein composition of human suction-blister interstitial fluid. J Lipid Res. 1987 ; 28: 629-641
61. Mackness MI, Mackness B, Arrol S, et al. Presence of paraoxonase in human interstitial fluid. FEBS Lett. 1997 ; 416: 377-380